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Preface 
The reasons for this study were multi-factorial, but mostly due to some interesting data 
obtained from a pilot study conducted at University College London (UCL). In that study, the 
coagulation effects in vitro of two hetastarch solutions were compared with two crystalloids by 
means of thrombelastography (TEG®). The fluids compared were: 
1. Hespan® (HES), a high molecular weight hetastarch (450kDa/O. ?substitution 
ratio) in a 0.9% saline solution - Laevosan, Austria. 
2. Hextend® (HEX), also a high molecular weight hetastarch (670/0.75 substitution 
ratio) in a balanced electrolyte, lactate and glucose solution - BioTime Inc, 
Berkeley, California, USA. 
3. Saline 0.9% 
4. Hartmann's Solution (Ringer's Lactate) 
The crystalloids revealed no surprising differences known from previous published data, but 
data obtained from the hetastarch solutions revealed contradictory results to known in vivo 
results found in a phase Ill trial.17 This previous Phase Ill in vivo trial showed that HEX 
haemodilution produced a superior coagulation profile to HES, along with a significantly 
shorter r-time than HES. There was also a significantly smaller transfused volume of blood 
than HES in the HEX-treated patients. 17 This Phase Ill study prompted the initial UCL in vitro 
haemodilution study mentioned above. In the UCL study, there were significantly impaired 
TEG® results, indicating severe hypocoagulability with HEX, when compared with HES. This 
included prolonged r-and k-times, as well as reduced a-angles and maximum amplitudes in 
the HEX group, compared with HES and crystalloid groups. 
Many theories were discussed for these controversial UCL results, but the thought was that a 
container-effect could have been responsible, as the in vitro UCL study methodology included 
the use of a polycarbonate container for initial storage, as well as for haemodilution of the 
blood in vitro. In view of the known wettable surface, as well as a strong negative surface 
charge of polycarbonate, it was suggested that the container surface itself could have 
affected coagulation. When different ionic compositions of the various fluids and starches 
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were taken into account, it seemed possible that some interaction between the fluids and the 
material of the containers could have induced or inhibited coagulation at the container 
surface. The suspicion was that the observed change in TEG® variables was likely due to a 
methodologic idiosyncrasy. 
Previous track record of haemodilution and TEG research at the University of Cape Town 
made it an obvious setting for exploration of this problem. Preparations were thus made to 
test container effects with haemodilution in vitro at Prof MFM James' anaesthesia laboratory 
at the University of Cape Town. The hypothesis was that the use of polypropylene and 
polycarbonate containers, with their different chemical and surface properties, would lead to a 
variability in TEG® results obtained from fresh whole blood, as well as blood diluted with 
various fluid solutions. 
Choosing TEG® as a monitor of coagulation was essential, as it has a well-established track 
record in monitoring coagulation effects in trials of haemodilution (in vitro and in vivo). 9 TEG® 
produces reliable and quick results, giving a reflection of global coagulation function. It, along 
with the Sonoclot®, are the only two devices which can reliably diagnose a hypercoagulable 
state.6•21 More will be mentioned on the TEG® later. 
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Introduction 
Fluid therapy is an important part of the global medical management of patients. Improved 
outcomes are attributed purely to rational, appropriate fluid management of patients.7 Peri-
operative fluid optimisation is an important determinant of post-operative morbidity.4·48 
However, apart from monitoring cardiovascular and respiratory function, urine output, routine 
haematology and biochemistry indices, coagulation status of the patient should be 
considered. This is often ignored in fluid therapy, but may have disastrous effects if not 
considered. Blood coagulability can be affected by the volume, speed and type of 
intravenous fluid being administered. 
Crystal/aids: 
It is well known that crystalloids induce a state of hypercoagulability at mild to moderate 
haemodilution,40•41 regardless of the type of crystalloid. This is well observed both in vitro, as 
well as in vivo. Two studies are of special relevance to the clinical setting ; Janvrin 
documented an increased deep venous thrombosis (DVT) rate associated with crystalloid 
administration, and Heather described a DVT predictor test using TEG and crystalloid dilution 
in vitro.19'23 
Colloids: 
Colloids have a more complex effect on coagulation, depending on the type and sub-type of 
colloid. For example, the dextrans are known to inhibit coagulation by means of von 
Willebrand factor inhibition, leading to a clinical state similar to von Willebrand disease.2 The 
dextrans have been reported as improving the rheologic properties of blood, as well as 
possessing a mild anticoagulant effect. This has led to the use of dextrans for thrombo-
embolic prophylaxis clinically. 2 
The hetastarch (HES) solutions have a very complex range of effects, where the high 
molecular weight, highly substituted, high C2:C6 ratio starches have the most deleterious 
effects on coagulation.50 
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Albumin seems to have minimal or no coagulation effects at mild to moderate 
haemodilution,49 but this may well not be the case at high dilutions, where the calcium-binding 
effects of albumin may leave the ionised calcium level too low to enable normal coagulation.9 
The gelatins also have minimal coagulation effects at mild to moderate haemodilution, but can 
inhibit coagulation formation at large doses.47 This is due to gelatin being a denatured 
collagen, which binds fibronectin. It is thus incorporated into the forming clot, resulting in 
reduced total clot strength and weight. 29 
9 
Coagulation: 
The important thing to remember about the coagulation system is that there is always a 
balance between procoagulant and anticoagulant systems (fig 1 ). 





Surface of platelet (Primary Haemostasis) 
Thrombi~ FibrinogenT Stable Clo,_. Lysis 
XIII 
Index: Basic coagulation rests upon stimulation of intrinsic (by contact activation with subendothelial 
tissues) or extrinsic (activation of factor VII by tissue factor) pathways. These stimulate the final common 
pathway (factor X) to generate thrombin from prothrombin. Thrombin catalyses the conversion of 
fibrinogen to fibrin monomers, which then polymerise under the control of factor XIII to form a stable clot. 
Besides primary haemostasis by platelet adhesion and aggregation, and clotting cascade activation, the 
third important process is fibrinolysis . 
Vascular injury triggers both the coagulation and fibrinolytic systems, and this is essential to 
maintain homeostasis. 
Primary Haemostasis: 
The initial physiological responses to vascular injury involve vasoconstriction and mechanical 
occlusion with an aggregate of platelets (the platelet plug), in addition to initiation of the 
coagulation system. Coagulation requires the activation of a cascade of enzymes; a 
biological amplification system where the few initiators sequentially activate a chain of 
precursor enzymes to generate thrombin. This thrombin activates circulating fibrinogen to 
form fibrin and this in turn enmeshes platelets at the site of injury producing a firm 
haemostatic plug, a blood clot, from the previous rather fragile platelet plug. 
The scale of amplification is vast with one mole of initially activated enzyme generating up to 
2x108 moles of fibrin. Local concentration of the circulating clotting factor enzymes is 
achieved through activation of the cascade by surface mediated reactions on expressed 
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collagen , tissue factors (lipoproteins released from damaged cells) and by platelet factor 3 
(PF3) a platelet membrane phospholipid which becomes exposed during platelet aggregation 
and the formation of the initial plug . 
Coagulation factors are mostly either enzyme precursors (all serine proteases, hydrolysing 
peptide bonds with serine residues at there active site except factor XI 11 , a transglutaminase) 
or co-factors, with factor I being fibrinogen, the fibrin monomer subunit precursor. 
Table 1: 
Factor Name Active Form 
I Fibrinogen Fibrin Subunit 
II Prothrombin Serine Protease 
Ill Tissue factor (lipoprotein form damaged cells) Cofactor 
IV Calcium Cofactor 
V Proaccelerin Cofactor 
VII Proconvertin Serine Protease 
VIII Von Willebrand Factor Cofactor 
IX Christmas factor Serine Protease 
X Stuart Prower factor Serine Protease 
XI Plasma Thromboplastin Anticedent Serine Protease 
XII Hageman (contact) Factor Serine Protease 
XIII Fibrin Stabilising factor Transglutaminase 
Prekallekrein (Fletchers factor) Serine Protease 
High molecular weight kininogen Cofactor 
The Intrinsic System: 
Exposed collagen and other negatively charged subunits of the damaged endothelium trigger 
the intrinsic system by activating factor XII. This in turn both activates factor XI and converts 
prekallekrein into kallekrein, the latter having an autocatalytic effect enhancing further 
activation of factor XII as well as an indirect vasoactive effect by binding factor XI to High 
Molecular Weight Kininogen (HMWK) cleaving the vasoactive peptide bradykinin from 
HMWK. 
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Figure 2: Coagulation Cascade 
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FINAL COMMON PATHWAY 
Index: Figure 2 provides a diagrammatic representation of the coagulation cascade to the point of stable 
fibrin clot formation. 
12 
Activated factor XI in turn activates factor IX, which, in association with cofactors IV & VIII 
activates factor X on PF3. This step in the cascade marks the start of the final common 
pathway where intrinsic & extrinsic systems merge to generate thrombin and, ultimately the 
final stable blood clot. 
The Extrinsic System: 
This is activated directly by lipoproteins released from damaged cells, and these activate 
factor VII, which in turn activates factor X and once more leads to the final common pathway. 
The Final Common Pathway: 
Here, factor Xa along with factors IV, V and PF3 facilitate conversion of prothrombin to 
thrombin which in turn both cleaves fibrin from fibrinogen and activates factor XII 1. The fibrin 
monomers spontaneously polymerise, and the polymer is further stabilised with covalent bond 
cross-links in the presence of Xllla and calcium. Fibrin enmeshes itself between platelets, 
anchoring them to the sites of damage. Within 24-28 hours, the platelets autolyse, 
transforming the plug into a solid fibrinous mass. Thrombin's role in clotting is pivotal as can 
be seen in figure 2, being responsible for onward conversion of fibrinogen to fibrin and thence 
to its stable polymer via activation of factor XI 11 as well as a positive feedback on cofactors 
VIII & V. Additionally it enhances platelet aggregation and externalisation of PF3, required for 
factor X activation. 
From this brief discussion it will be apparent that the intrinsic and extrinsic clotting systems 
complement one another. Some authors prefer to see them as one system rather than two 
complementary pathways. The boundaries between these pathways have become less 
defined, with cross activation between the systems, for example tissue factor activated factor 
VII enhancing intrinsic coagulation. Tissue injury will directly stimulate the extrinsic system 
generating thrombin, which then has a positive feedback on the intrinsic system. Clinically, 
quite severe bleeding diatheses are seen in individuals deficient in one factor, demonstrating 
the need for both systems to be functional to achieve homeostasis. 
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Physiological Limitation of Coagulation: 
In order to prevent potentially fatal thrombosis there must be a mechanism for limiting the 
coagulation cascade and this is provided in 3 ways: 
(1) Inhibition of Activated Clotting Factors 
Circulating inhibitors directly inactivate enzymes by binding with them to form high molecular 
weight complexes. The most potent of these is antithrombin Ill (whose activity is potentiated 
by heparin), which binds thrombin and other serine protease clotting factors, as do ar 
macroglobulin, a2-antiplasmin and arantitrypsin. 
Another circulating inhibitor is the serine protease Protein C, activated by the bound complex 
of thrombin and endothelial cell. This destroys factors V & VIII thus preventing further 
thrombin formation. Protein Sis also of endothelial origin and its function is to enhance the 
action of Protein C. 
(2) Blood Flow 
Part of the general physiological response to injury includes hyperaemia of the injured part. 
This facilitates local dilution and dispersal of activated clotting factors from the periphery of 
the injured site prior to fibrin formation, and these are then carried to the liver and removed by 
the reticule-endothelial system. 
(3) Fibrin Degradation Products (FDPs) 
Plasmin (see below) limits the evolving clot by splitting fibrin, fibrinogen and factors V and 
VIII, creating split products which are, in turn, competitive inhibitors of both thrombin and fibrin 
polymerisation. 
Fibrinolysis: 
As with coagulation, fibrinolysis is a normal haemostatic response to vascular injury and may 
be activated intrinsically (by activators of vessel wall origin) or extrinsically (by activators from 
tissues). Activation produces the serine protease, plasmin, from its precursor, plasminogen, 
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and this enzyme hydrolyses arginine and lysine peptide bonds, destroying fibrinogen, fibrin, 
factors V and VIII, and many other proteins. Lysed products of fibrinogen and fibrin (FDPs) 
themselves have an anticoagulant effect as mentioned earlier (Fig 3). 
Circulating plasmin is inactivated by arantiplasmin and a2-macroglobulin; thus preventing 
widespread destruction of fibrinogen and clotting factors .16 
Figure 3: Fibrinolytic Response 
Intrinsic Activation 












Index: Figure 3 displays the physiologic limitation of coagulation, where intrinsic and extrinsic stimulation 
of plasminogen occurs. The net result is increased plasmin formation, which cleaves fibrin . 
15 
Thrombelastography 
The thrombelastograph® (TEG®, Haemoscope®, Skokie, IL) is enjoying a resurgence in use 
for point-of-care monitoring of coagulation (especially cardiac surgery13.45 and liver 
transplantation24), in addition to its established track record for research purposes. TEG® 
monitoring has been associated with reduced blood product usage due to the focussed goal-
directed administration of appropriate blood products or drugs during bleeding states.44 In the 
research setting it has been used extensively to investigate the coagulation effects of 
haemodilution, both in vitro and in vivo. 32•40·42 The benefit is that it provides a quick 
assessment of global coagulation and the interplay of coagulation systems and pathways.28 It 
is possible to perform samples on fresh whole blood, citrated blood, whole plasma, platelet-
rich or platelet-poor plasma. Samples can be analysed with or without using coagulation 
activators, e.g. celite, kaolin, tissue factor. The disadvantages of the TEG® are that it cannot 
quantify the platelet-endothelial interaction, neither can it diagnose a specific factor 
abnormality or deficiency. 
Figure 4: TEG Mechanism of Action 
Torsion wire 
Cup-- .36 ml whole blood 
(Clotted) 
Reproduced with permission: © Haemoscope Corp, Skokie, IL 
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In performing a TEG® the machine, together with a plastic cup and pin or piston is pre-heated 
to 37 degrees Celsius . Native, whole blood is then drawn and inserted into the plastic cup, 
usually as a volume of 0.36 ml (depending on the type of TEG® to be performed) 2-6 minutes 
later. The blood-air interface is covered with mineral oil to prevent evaporation and increased 
surface tension. The TEG® is then commenced , running for a time period of 1-2 hours. The 
cup rotates to and fro through an arc of 4°45' over a 10 second period, with a short pause at 
either end to overcome kinetic forces. The pin is suspended in the blood by means of a 
torsion wire, which senses movement of the pin (see figure 4). The trace obtained is due to 
the oscillating action of the cup being transmitted to the pin as strands of fibrin form within the 
blood sample. The movement sensed by the torsion wire is then transmitted as a signal to 
the output.28 The original machines produced a trace by the oscillating action of a heated 
stylus on heat-sensitive paper, while the current machines produce a computer output. These 
traces are then analysed by various times, measurements and angles - r time, K time, r + K 
time, alpha angle, maximum amplitude (MA) being the baseline measured variables. The 
relevance of these variables is that they each reflect a different component or relationship 
within the finely balanced coagulation cascade (see figure 5). 
Figure 5: TEG trace and correlation with coagulation pathways and tests 
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Modified from von Kier and Smith ,© J Cardiothor Vase Anesth 2000; 14 (Suppl 1 ). Reproduced with permission. 
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Coagulation, being such a dynamic process, balancing pro-coagulant, anticoagulant and 
fibrinolytic systems to give a final clot formation rate, total strength, as well as fibrinolytic 
profile, is very susceptible to manipulation of the balance. For example, addition of contact 
activation factors (e.g. celite) to a sample in vitro will produce an accelerated coagulation 
response.5 The release of thromboplastins associated with an amniotic fluid embolus in a 
parturient, will strongly activate the extrinsic coagulation pathway, producing a potentially life-
threatening disseminated intravascular coagulopathy (DIC). 27 
Containers 
Glass is a strong contact activator, therefore blood specimens stored in non-siliconised glass 
tubes, albeit for a short period, may produce accelerated laboratory-based coagulation 
tests.14 
It is therefore recommended that polypropylene or glass (with a siliconised internal surface) 
containers should be used for handling of blood samples, as unsiliconised glass containers 
cause contact activation of the intrinsic coagulation pathway, as well as leucocyte and platelet 
adhesion.3•31 Polypropylene prevents this surface activation of factor XII (Hageman Factor), 36 
and therefore also causes a minimal thrombogenic response. 26 The TEG manufacturers 
(Haemoscope Corp, Skokie, IL) also recommend use of polypropylene containers in handling 
of blood specimens. Polycarbonate surfaces are also implicated in altering coagulation, 
thought usually to be due to a surface activation, however, there are more issues involved 
than simple contact activation or inhibition. These issues will be covered in greater detail in 
the discussion, as it is useful to first review the trial data and results . 
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Study Outline: 
The purpose of this observational study was to determine the TEG® coagulation effects of 
polypropylene and polycarbonate containers on fresh whole blood and in vitro haemodiluted 
samples. The hypothesis was that significant coagulation variability is found with different 
polymer containers, especially when fluids with altered ionic compositions are compared. The 
study was therefore performed diluting fresh whole blood by 50% with : 
1. A balanced electrolyte crystalloid similar to Ringer's Lactate (Balsol® - lntramed, 
South Africa), 
2. HES 450 kDa/0.7 in 0.9% NaCl (Sabax Hetastarch 6%® - Adcock-Ingram Critical 
Care, South Africa), and 
3. HES 670 kDa/0. 75 in a balanced electrolyte and glucose solution (Hextend® -
BioTime Inc, CA). 
Control, whole blood samples were also used as a reference for the dilution effects. Dilutions 
of 50% were chosen as a good starting point, representing severe haemodilution conditions. 
The ionic compositions of the fluids used are tabulated below. Note that Balsol®, although 
similar to a Ringer's type solution, does not contain lactate, but rather bicarbonate, and also 
has no calcium content. 
Electrolyte Composition (mmol/1) 
Electrolyte Hextend® Sabax Balsol® 
Hetastarch 6%® 
Sodium 143 154 130 
Chloride 124 154 109 
Lactate 28 0 0 
Calcium 2.5 0 0 
Potassium 3 0 4 
Magnesium 0.45 0 1.5 
HC03- 0 0 28 
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The hypothesis mentioned above was tested by performing two separate studies, after 
approval of the protocols by the UCT Human Research Ethics Committee. These studies will 
be described in the following two chapters. 
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Study 1 Methods 
The study was performed using eight healthy volunteers. Exclusion criteria were individuals 
with a history of bleeding disorders, renal disease, hepatic disease, those who were taking 
coagulation-altering drugs, or anybody who had received an intravenous infusion of any type 
of fluid in the preceding 3 months. Informed verbal consent was obtained from all volunteers. 
Blood was taken twice (90 minutes apart) by a two-syringe technique from a free-flowing 
forearm vein (opposite arm for second sampling) into polypropylene syringes (Curity®, South 
Africa) using 21g butterfly needles (Techno Med cc, South Africa). The first syringe of blood 
was discarded, and blood from the second syringe was deposited into a 5ml polypropylene 
container (lnfopac, South Africa). Blood from this reservoir container was sampled by pipette 
for haemodilution purposes (described below). Figure 6 displays the methods and handling of 
the blood in Study 1. 
The second step, i.e. the haemodilution, was performed using four polypropylene (lnfopac, 
South Africa) and four polycarbonate (Tool & Carbide, South Africa) tubes. All these tubes 
were pre-warmed in a 37°C water bath, and will be referred to as the dilution tubes. 
Preparation of these tubes involved placement of either 500µ1 test fluid (as described above) 
or no fluid for the control samples. From the reservoir container mentioned in the paragraph 
above, 500µ1 blood was pipetted into each dilution tube containing test fluid , or 1 ml was 
deposited into each control tube. Therefore all dilution tubes contained a total of 1ml (100% 
blood, or 50% blood with 50% fluid) . It follows that "Tube 2" in figure 6 was either a 
polypropylene or polycarbonate tube as described (PP-d1 or PC-d1 ). 
All tubes, including control samples, were then gently inverted 8 times. Both the 
polypropylene and polycarbonate tubes had stoppers made of polypropylene. Thereafter 
360µ1 was pipetted out of each of these dilution containers into a calibrated TEG® analyser 
(Haemoscope Corp, Skokie, IL). The TEG® machines were pre-warmed to a temperature of 
37°C, and TEG® analysis was commenced at 5 minutes after venepuncture. Each TEG® 
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sample surface was then covered with mineral oil. All samples were pipetted into dilution 
tubes and TEG cuvettes using polypropylene pipette tips. 
Control samples as well as all fluids (Balsol®, Sabax Hetastarch 6%®, and Hextend®) were 
therefore initially briefly stored in polypropylene reservoir containers (PP-r1, Figure 6), and 
haemodiluted thereafter in either polypropylene and polycarbonate containers (PP-d1 and 
PC-d1, Figure 6). 















1 i r 1 
HES HEX Control BSL 




Where: PP-r1 and PP-d1 = Polypropylene Tubes (lnfopac, South Africa) 
PC-d1 = Polycarbonate Tubes (Tool and Carbide, South Africa) 
Control = Undiluted fresh whole blood samples 
BSL = Balsol® 50% Dilution 
HES = Sabax Hetastarch® 50% Dilution 




The "reservoir'' tube was used only for initial storage of blood prior to pipetting for haemodilution 
purposes in the "dilution" tubes 
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Study 2 Methods 
The second study was also performed using eight healthy volunteers. Exclusion criteria were 
the same as in study one. Informed verbal consent was obtained from all volunteers. 
Sampling methods remained identical to study one, described as follows. Blood was taken 
twice (90 minutes apart) by a two-syringe technique from a free-flowing forearm vein 
(opposite arm for second sampling) into polypropylene syringes (Curity®, South Africa) using 
21g butterfly needles (Techno Med cc, South Africa). The first syringe of blood was 
discarded. 
From there, handling differed by storing and diluting in different containers to study one. 
Blood from the second syringe was deposited into a 5ml polycarbonate container (Bibby 
Sterilin Ltd, Staffordshire, UK). Out of this reservoir container, it was pipetted for 
haemodilution purposes (described below). Figure 7 displays the methods and handling of 
the blood in Study 2. 
The second step, i.e. the haemodilution, was performed using polypropylene (lnfopac, South 
Africa) and polycarbonate (Pennine Healthcare, Derby, UK) tubes. Preparation of these 
tubes involved placement of either 500µ1 test fluid (as described above) or no fluid for the 
control samples. All these tubes were also pre-warmed in a 37°C water bath. From the 
reservoir container, 500µ1 blood was pipetted into each dilution tube containing test fluid, or 
1 ml was deposited into each control tube. Therefore all dilution tubes contained a total of 1 ml 
(100% blood, or 50% blood with 50% fluid). It follows that "Tube 2" in figure 7 was either a 
polypropylene or polycarbonate tube as described (PP-d2 or PC-d2). 
The reasons for changing both reservoir and dilution polycarbonate tubes in the second study 
were due to the need to replicate the exact UCL pilot study methodology. 
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All tubes, including control samples, were then gently inverted 8 times. Thereafter 360µ1 was 
pipetted out of each of these dilution containers into a calibrated TEG® analyser 
(Haemoscope Corp, Skokie, IL). The TEG® machines were pre-warmed to a temperature of 
37°C, and TEG® analysis was commenced at 5 minutes after venepuncture. Each TEG® 
sample surface was then covered with mineral oil to prevent evaporation. As in trial 1, all 
samples were pipetted into dilution tubes and TEG cuvettes using polypropylene tips. 
Figure 7: Study 2 Methods 

















Control BSL HES HEX Control BSL HES 
500µ1 500µ1 500µ1 500µ1 500µ1 
Where: PP-d2 = Polypropylene Tubes (lnfopac, South Africa) 
PC-r2 = Polycarbonate Tubes (Bibby Sterilin Ltd, Staffordshire, UK) 
PC-d2 = Polycarbonate Tubes (Pennine Healthcare, Derby, UK) 
Control = Undiluted fresh whole blood samples 
BSL = Balsol® 50% Dilution 
HES = Sabax Hetastarch® 50% Dilution 




TEG® analysis of each sample continued for a minimum period of 90 minutes. The r-times, 
k-times, a-angles and maximum amplitude were measured and analysed statistically. 
Study two was similar to study one, but with two important changes. The first change was 
using a polycarbonate container as the initial "reservoir'' of the blood (undiluted blood 
immediately placed in these tubes) for pipetting purposes (PC-r2 in figure 7). This compares 
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with using polypropylene in the first limb. The second change was using a separate type (i.e. 
manufacturer) of polycarbonate tube for haemodilution (mixing) purposes (PC-d2 in figure 7). 
There were thus three separate types of polycarbonate tubes used in the study as a whole. 
On the other hand, only one type of polypropylene container was used throughout the study. 
The first change was done to assess the effects of the initial storage (albeit less than a couple 
of minutes) of the blood prior to pipetting. Our hypothesis for this was that the type of 
container used in this first step (i.e. storage prior to haemodilution) is of paramount 
importance to prevent any adverse effects on coagulation. The second change was purely to 
assess a separate type of polycarbonate container on the mixing of blood and fluid . Attempts 
were made, unsuccessfully, to establish what types of polycarbonate were used by the 
different manufacturers. It is likely, however, that small differences would be found, from 
types of plastic to general manufacturing process, leading to altered laboratory effects. 
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Statistical Analysis: 
One-way ANOVA, multivariate analysis of variance and paired t-tests were used to analyse 
differences within each limb. Unpaired t-tests were used to analyse differences between 
limbs. Post hoc LSD testing was used to identify individual differences between limbs where 
these were demonstrated to exist by the ANOVA technique. These techniques were 
performed using STATISTICA® software package on an IBM compatible personal computer, 
running on a Windows®-based platform. 




Analysis of study 1 revealed no significant differences between the same fluids when diluted 
in the different plastic containers. Furthermore, there were no differences between the two 
starches, regardless of the container in which dilution was performed (Figs 8-11 ). There were 
also no differences in the whole blood controls. 
Differences were found when comparing control samples and the crystalloid samples with the 
colloids. These results conform with previously described effects of crystalloid 
haemodilution 10·40 and will not be discussed in this thesis, as they do not add to the 
understanding of fluid and container effects (Figs 8-11 ). Briefly examining these results, it 
was apparent that both HES and HEX produced a hypocoagulable state (in all measured TEG 
variables) compared with BSL and fresh whole blood control samples. Furthermore, 
significant differences, reflecting a crystalloid hypercoagulability were found with k-times and 
a-angles when compared with whole blood controls. Thus, although there were significant 
coagulation differences attributable to the diluent fluid used, there were no differences 
attributable to the containers used for either the initial storage or for dilution. 
What is relevant to this thesis, is that the results of study one suggest that the paradoxical 
effects at the blood-container interface were not found with haemodilution using 
polypropylene reservoir containers and polypropylene or polycarbonate dilution tubes. These 
results are in stark contrast to the data generated by the UCL pilot study mentioned in the 
introduction. It follows, therefore, that our second study, using the same tubes as in the pilot 
study combined with fluids of varying composition (both ionic and crystalloid or colloid) , would 
replicate the paradoxical effects initially observed. 
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Study 1 : r-tlmes 
C-PP C-PC BSL-PP BSL-PC HES-PP HES-PC HEX-PP HEX-PC 
Index: See below. 
Figure 9: Study 1 k-time means + standard deviations 








C-PP C-PC BSL-PP BSL -PC HES-PP HES-PC HEX-PP HEX-PC 
Figs 8-9: All reservoir containers PP-r1 (see figure 6), but DILUTIONS subsequently performed 
in PP-d1 or PC-d1 tubes (Figure 6) 
C = Undiluted fresh whole blood controls 
PP = Polypropylene dilution tubes 
PC = Polycarbonate dilution tubes 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
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Figure 10: Study 1 alpha angle means + standard deviations 








C-PP C-PC BSL-PP BSL-PC HES-PP HES-PC HEX-PP HEX-PC 
Index: See below 
Figure 11: Study 1 maximum amplitude means + standard deviations 








C-PP C-PC BSL-PP BSL-PC HES-PP HES-PC HEX-PP HEX-PC 
Figs 10-11: All reservoir containers PP-r1 (see figure 6), but DILUTIONS subsequently performed 
in PP-d1 or PC-d1 tubes (Figure 6) 
C = Undiluted fresh whole blood controls 
PP = Polypropylene dilution tubes 
PC = Polycarbonate dilution tubes 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
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Study 2 
The statistically significant results of Study 2 are summarised in Table 2. 
Significant differences were already seen between the undiluted control samples placed in 
either polypropylene or polycarbonate dilution tubes in study 2. The samples were all first 
placed in a polycarbonate (PC-r2, figure 7) reservoir prior to pipetting into the dilution tubes 
(PP-d2, and PC-d2, figure 7). The samples placed in polypropylene dilution tubes (PP-d2) 
displayed shorter k-times, enhanced alpha angles, and enhanced maximum amplitudes when 
compared with those samples placed in polycarbonate dilution tubes (PC-d2, figure 7). 
HES diluted in polypropylene displayed prolonged r-times to HES diluted in polycarbonate, as 
well as to HEX diluted in polypropylene. 
HEX diluted in polypropylene displayed shorter k-times than HEX in polycarbonate dilution 
tubes. 
Table 2: Study Limb 2 Results 
r-time: HES-PP > HES-PC 





Control-PP < Control-PC 
HEX-PP < HEX-PC 
Control-PP > Control-PC 
Control-PP > Control-PC 
PP=Polypropylene 
PC=Polycarbonate 
Fluid references as in Table 1 







The graphical representation of the results of study 2 is found in figures 12-15. 
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Figure 12: Study 2 r-time means+ standard deviations 
mm 















Fluid references as in Table 1 
p-values as quoted 
r-time: HES-PP > HES-PC 
HES-PP > HEX-PP 
p<0.05 
p<0.05 












Study 2: k-tlmes 
C·PP C·PC BSL·PP BSL·PC HES-PP HES-PC HEX-PP HEX-PC 
Figs 12-13: All reservoir containers Pc-r2 (see figure 7), but DILUTIONS subsequently performed 
in PP·d2 or PC·d2 tubes (Figure 7) 
C = Undiluted fresh whole blood controls 
PP = Polypropylene dilution tubes 
PC = Polycarbonate dilution tubes 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
k·time: Control-PP < Control-PC 
















Study 2: alpha angles 
C-PP C-PC BSL-PP BSL-PC HES-PP HES-PC HEX-PP HEX-PC 
a-angle: Control-PP > Control-PC p=0.02 
Figure 15: Study 2 maximum amplitude means + standard deviations 








C-PP C-PC BSL-PP BSL-PC HES-PP HES-PC HEX-PP HEX-PC 
Figs 14-15: All reservoir containers Pc-r2 (see figure 7), but DILUTIONS subsequently performed 
in PP-d2 or PC-d2 tubes (Figure 7) 
C = Undiluted fresh whole blood controls 
PP = Polypropylene dilution tubes 
PC = Polycarbonate dilution tubes 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
MA: Control-PP > Control-PC p=0.01 
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Reservoir Effects 
Initial grouping of all samples (i.e. all fluids and controls) diluted in polypropylene containers 
only in both studies (i.e. PP-d1 in figure 6, and PP-d2 in figure 7, not PC tubes) showed a 
shortened r-time (p=0.01 ), shortened k-time (p=0.0002), and raised a-angle (p<0.0001) in 
Study 1 when compared with samples stored in polycarbonate reservoir tubes in Study 2. In 
other words, there was a longer time to initiation, as well as a reduced rate of clot formation in 
Study 2, regardless of haemodilution. No difference was found in the grouped MA values. 
The only methodologic difference examined between studies, using this type of grouping 
analysis, was the initial "reservoir" container used. The samples diluted in polycarbonate 
containers in both studies (PC-d1 and PC-d2) were thus ignored in this analysis. 
Table 3: Comparison of Reservoir Container Effects 





HEX (S1) < HES (S2) p=0.002 
HES (S1) < HES (S2) 
HES (S1) < HEX (S2) 
HEX (S1) < HES (S2) 
HEX (S1) < HEX (S2) 
Control ( S 1 ) > Control ( S2) 
BSL (S 1) > BSL (S2) 
HES (S1) > HES (S2) 
HES (S1) > HEX (S2) 
HEX (S1) > HES (S2) 
HEX (S1) > HEX (S2) 
HES (S1) > HES (S2) 
HES (S1) > HEX (S2) 
S1 =Study 1 
S2=Study 2 
Control = Undiluted fresh whole blood 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 













Table 3 above shows the statistically significant differences between the various control and 
fluid diluted samples where the blood was initially placed into a polypropylene (S 1 = Study 1) 
or polycarbonate (S2 = Study 2) reservoir container and subsequently haemodiluted in 
polypropylene containers only. 
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Both HES and HEX in study 1 produced significantly shorter r-times than HES in study 2. A 
similar picture was seen with the k-times, where HES and HEX in study 1 produced 
significantly shorter k-times to both HES and HEX in study 2. 
Undiluted control samples had increased alpha angles in study 1 compared with the controls 
in study 2. BSL also displayed raised alpha angles to itself from study 1 to study 2. Once 
again, HES and HEX produced significant differences across studies, where they both had 
raised alpha angles compared to HES and HEX in study 2. 
Finally, HES in study 1 had higher maximum amplitudes compared with HES and HEX in 
study 2. 
Thus, the use of polycarbonate containers for initial storage of blood samples resulted in 
some degree of inhibition of the TEG® regardless of dilution, or the type of diluent used. 
See figures 16-19 for graphical representation of these data comparing reservoir effects. P-
values are not quoted in the figures, as they are available in table 3. 
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r • times 
!•PP Reservoir •PC Reservoir I 
Control BSL HES 
r-times: HES (S1) < HES (S2) 




Figure 17: k-times Study1 v Study 2 Reservoir Effects 
mm 
k • times 











BSL HES HEX 
Reservoir containers PP-r1 or PC-r2, but all DILUTIONS subsequently performed only 
in PP (PP-d1 or PP-d2, figures 6 and 7). 
Control = Undiluted fresh whole blood 
PP = Polypropylene 
PC = Polycarbonate 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
k-times: HES (S1) < HES (S2) 
HES (S1) < HEX (S2) 
HEX (S1) < HES (S2) 



















Control (S1) > Control (S2) 
BSL (S1) > BSL (S2) 
HES (S1) > HES (S2) 
HES (S1) > HEX (S2) 
HEX (S1) > HES (S2) 
















I •PP Reservoir •PC Reservoir J 
Control BSL HES HEX 
Figs 18-19: Reservoir containers PP-r1 or PC-r2, but all DILUTIONS subsequently performed only 
in PP (PP-d1 or PP-d2, figures 6 and 7). 
Control = Undiluted fresh whole blood 
PP = Polypropylene 
PC = Polycarbonate 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
MA: HES (S1) > HES (S2) p<0.05 
HES (S1) > HEX (S2) p=0.01 
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All Polypropylene versus All Polycarbonate 
When examining results of samples initially stored and diluted in only polypropylene (from 
Study 1) or only polycarbonate (Study 2) containers, the following results were found. Control 
whole blood samples in polypropylene revealed consistently shorter r-times and k-times, as 
well as increased a-angles and maximum amplitudes than those in polycarbonate (p<0.01). 
Balsol® (BSL) in polypropylene only produced a significantly shorter k-time (p=0.02), but had 
strong trends in r-times (p=0.1) and a-angles (p=0.06) compared to polycarbonate handling. 
HES produced a raised mean a-angle in polypropylene (p<0.03), whereas HEX produced 
shorter k-times, raised a-angles and MA values in the polypropylene versus the 
polycarbonate group. 
There were no significant differences between HES and HEX when blood was stored and 
diluted in polypropylene containers. On the other hand, k-times were shorter (p<0.05) and 
MA values were raised (p<0.01) in HES versus HEX in polycarbonate containers. 
When comparing the starches with control samples, in the polypropylene group, the r-times 
were prolonged (ps;0.05), and MA's were lower (p<0.001 ), with HES and HEX. When 
samples were stored and diluted in polycarbonate tubes, prolonged r-times (p<0.025) were 
found with HEX, and the MA's were less with HES as well as HEX (p<0.002), versus control. 
These results concur with those found in the UCL pilot study, where decreased coagulation 
was found with Hextend® dilution (versus the saline based hetastarch solution) after the initial 
storage of fresh blood in polycarbonate reservoirs. 
The differences of performance of crystalloid and starch solutions provided, in some 
circumstances, paradoxical results when containers were changed. When comparing results 
with BSL (in PP), the r-times of HES in polypropylene were prolonged (p<0.01 ), whereas only 
HEX in polycarbonate (and not HES) had significantly longer r-times than BSL polycarbonate 
(p<O.O 1 ). HES and HEX produced consistently prolonged k-times, as well as raised a-angles 
compared with BSL in polypropylene and polycarbonate containers (ps;0.05). MA's were 
reduced in both HES and HEX versus BSL in both container types (ps;0.005). 
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See figures 20-23 for graphical representation of all polypropylene or all polycarbonate 
handling of samples. 











C-PP BSL-PP HES-PP HEX-PP C-PC BSL-PC HES-PC HEX-PC 













C-PP BSL-PP HES-PP HEX-PP C-PC BSL-PC HES-PC HEX-PC 
Figs 20-21 : PP = All Polypropylene - solid bars on graph 
PC = All Polycarbonate - diagonal stripes on graph 
Control = Undiluted fresh whole blood 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
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C-PP SSL-PP HES-PP HEX-PP C-PC SSL-PC HES-PC HEX-PC 









C·PP SSL-PP HES-PP HEX-PP C-PC SSL-PC HES-PC HEX-PC 
Figs 22-23: PP = All Polypropylene - solid bars on graph 
PC = All Polycarbonate - diagonal stripes on graph 
Control = Undiluted fresh whole blood 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
Further graphical representation of all results of both studies can be seen in figures 24-27 
{appendix 1 ). 
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Polypropylene - Polycarbonate Differences (Study 2) 
If one closely examines the graphs of the Study 2 hetastarch fluid results, a fascinating 
picture emerges (figs 12-15). Firstly HES displays an improved coagulation profile when 
dilution is performed in polycarbonate dilution tubes ("HES-PC"), relative to being diluted in 
polypropylene tubes ("HES-PP"), whereas HEX displays a completely opposite profile, 
reflecting a less coagulable picture in polycarbonate ("HEX-PC") relative to polypropylene 
("HEX-PP"). Therefore, a separate analysis was performed of the differences encountered in 
TEG variables between the same fluids diluted in the two different types of dilution tubes (PP-
d1, PP-d2 or PC-d1, PC-d2) in both studies. In other words, the TEG variables of HES 
diluted in polypropylene were subtracted from those of HES diluted in polycarbonate for each 
study. The same was done for HEX. The results of these differences were then analysed by 
t-tests for HES versus HEX. 
There were no significant changes attributable to the diluent tube used in study 1 between the 
two fluids, see figure 24 below. Such differences as there were, were all in the same 
direction. The alteration in all TEG measures attributable to the container in which dilution 
was performed in study 2 was significantly different between HES and HEX, see figure 25 
below. In each case, the use of this specific polycarbonate container enhanced coagulation 
in the HES diluted samples, and inhibited coagulation in the HEX diluted samples. 
40 









Study 1 Differences 
p=0.4 p=0.3 p=0.6 p=0.6 
~ X 
r-times k-times Angles MaxAmpl 
Index: Figure 24 displays no difference due to diluent container and hetastarch fluid tested in study 1. 
This is in contrast to that found in study 2, figure 25 below. 









Study 2 Differences 
p = 0.015 p = 0.018 p = 0.023 p = 0.01 
[:;] X 
r-times k-times Angles MaxAmpl 
Index: These data reflect the differences between the results of HES in PP-d2 subtracted from HES in 
PC-d2, and HEX in PP-d2 subtracted from HEX in PC-d2. P-values of all TEG variables for HES versus 
HEX are significant. 
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Discussion 
Exposure of blood to foreign surfaces is commonplace in clinical and investigative medical 
practice. Numerous events occur at exposure to these surfaces, be it in vitro or in vivo. 
Protein adsorption, coagulation system activation, platelet adsorption, aggregation and 
activation, leucocyte adhesion, complement activation, as well as stimulation of inflammatory 
mediators are all known to play a part in this response. The type and extent of this response 
is highly dependent on many characteristics of the foreign surface being exposed, as well as 
the blood itself. Much research is being devoted to finding an ideal polymer or surface for 
implantable use, haemodialysis filtration, cardiopulmonary bypass materials, as well as for the 
in vitro handling of blood, and at the same time causing minimal host inflammatory or 
coagulation response. 
Standardisation of blood sampling and handling thereafter is important in producing reliable, 
reproducible results. Within an institution, where own reference values are determined and 
used, it is especially relevant to follow consistent methods for the handling of samples. 
Where methods and techniques vary between institutions and laboratories for the same 
investigations, caution must be exercised when results are compared out of the context of 
their own reference limits.38 Coagulation is a finely balanced system of pro-coagulation, 
anticoagulation and fibrinolysis .22 Without the presence of an intact, working endothelium 
when blood is sampled for coagulation testing, a vital system in haemostatic control is lost. 
Correct handling of this blood is essential for reliable laboratory and near-patient 
assessments to be made. Contact activation by use of a non-siliconised glass tube, for 
example, will cause activation of the intrinsic pathway, and possibly even the extrinsic 
pathway. 14 This would thereby produce false results in many tests of coagulation. TEG® is 
highly susceptible to these effects. 
Many of us may be lulled into a false sense of security in believing TEG® is a reliable, robust 
test in almost all situations. The reality is not far from this, as long as certain precautions and 
care are taken when using TEG® both for research as well as in the clinical setting. Blood 
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may incorrectly be placed in the nearest tube available for TEG® analysis, this often being of 
a polycarbonate material. We have shown that this could skew results, leading to incorrect 
interpretation and actions. 
Polycarbonate tubes (usually clear, hard, screw-top plastic tubes) are widely used in 
medicine. Polycarbonate is a strong, hard, amorphous thermoplastic.
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Its uses include urine 
collection for microscopy and culture, small pathology samples, as well as tissues and body 
fluids for microbiologic investigation. It is probably the most commonly found type of plastic 
tube we would find on the wards, as well as in theatre. This is why it may commonly be 
incorrectly used for initial non-citrated storage of fresh whole blood prior to near-patient 
testing of coagulation. 
CH3 0 
I /YY\_ II f--Q;-0- c- 0 
CH3 
Polycarbonate generalised chemical structure1 
The results of our study casts new, interesting light on the issue of blood handling prior to 
coagulation assessment in haemodilution studies. Not only does the material of the container 
used for initial storage of blood affect results, but also the container material in which it is 
haemodiluted. There are significant differences between the same fluids (mostly hydroxyethyl 
starch preparations) when haemodilution was performed in either polypropylene or 
polycarbonate tubes. Differences were also found in fresh whole blood control samples when 
different containers were used. 
These data show, amongst others, that simply using a polycarbonate tube (in place of a 
polypropylene tube) for storage of blood prior to haemodilution and TEG® analysis, causes a 
significantly slower time to clot formation, as well as impairing the rate of clot formation. This 
is found when all samples were grouped, as well as by individual comparisons of controls, 
and with various fluid dilutions (especially with hetastarch solutions). We have therefore 
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shown that the use of polycarbonate tubes just for initial storage of blood prior to 
haemodilution reproduces the anomaly found in the UCL pilot study. The interaction between 
this different blood-material interface, a physiologic electrolyte fluid composition, as well as 
the presence of hetastarch (as in Hextend®), produces an impaired TEG coagulation profile. 
This picture was not observed using polypropylene reservoir containers. 
Furthermore, individual differences in the coagulation effects of specific fluids, as well as 
between fluids of the same group are apparent. Some of these differences are highly 
significant, suggesting once again that certain polycarbonate surfaces adversely affect 
coagulation. For example, HES in Study 1 reflects a picture of faster clot formation times and 
rates, as well as greater total clot strength than the same HES in Study 2. There are also 
paradoxical differences between two different types of hetastarch solutions in the two limbs 
(see results listed above). HEX, stored and diluted in polypropylene produces less 
derangement of especially r-times than HES also stored and diluted in polypropylene. On the 
other hand, HES in polycarbonate produces less derangement of r-times than HEX treated in 
the same way. It is known that different groups of fluids produce characteristic coagulation 
effects, and that even within groups of fluids, coagulability is not necessarily the same.10·46·50 
What remains interesting in our data is the absence of paradoxical effects with the 
polycarbonate dilution tubes (Tool and Carbide, South Africa) in study 1. This may be due to 
the initial storage of blood in polypropylene reservoir containers, but it may also be due to the 
polycarbonate dilution tubes being of a different nature and composition to those used in the 
pilot study (and study 2 - UK manufacturers). This remains for further investigation. 
The use of polypropylene pipette tips could add an extra dimension to the trials, considering 
the importance of which material was used for storage and dilution of blood. On the other 
hand, all the samples were handled in exactly the same way from a pipetting point-of-view (all 
were pipetted using polypropylene tips). One would expect the resultant effect to be similar 
for all samples. Also, from our methods, it is clear that initial storage of blood in 
polycarbonate produces interesting, and sometimes paradoxical coagulation responses. It is 
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likely, therefore, that minimal effect on final TEG coagulation differences could be attributed to 
the pipette tips used. If polycarbonate tips were used, this may have revealed a very different 
picture, and possibly even with glass tips producing a strong contact activation. 
Previous work into biocompatibility implicates leucocyte and platelet adhesion and activation 
on bio-incompatible surfaces. This starts almost instantaneously, when blood is exposed to a 
foreign surface. The type of surface, texture and charge, play very important roles in this 
response seen. This then translates into varied coagulation effects if whole blood coagulation 
is measured - the direction and extent of response attributable to the factors mentioned. 
Further work revealed that different inflammatory mediators are released during blood 
coagulation in contact with different materials. 33 That study showed that complement 
activation was raised after blood exposure to Teflon and silicon-coated glass, a picture not 
seen to the same degree with polypropylene or polyurethane. Altered leucocyte reactivity 
was found in glass versus polypropylene and polyurethane surfaces. Inflammatory mediator 
release was not uniform across different materials tested. Other work interestingly shows that 
unsiliconised glass surfaces not only activate coagulation, but also enhance fibrinolysis by 







Polypropylene basic structure 1 
Polypropylene surfaces are non-wettable (i.e. hydrophobic), and minimal contact- and platelet 
activation occurs on polypropylene surfaces,36 as briefly alluded to in the introduction. It is 
also a long-lasting implantable polymer, used commonly in non-resorbable sutures, with 
minimal resultant inflammatory response.20 Polycarbonate has a highly polar, negatively 
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charged, wettable (hydrophilic) surface. Besides its use in medical containers and tubes, it is 
widely used in haemodialysis filters, as well as in blood oxygenators. 
Plastics become electrically charged during the manufacturing process, forming electrets on 
the surface. These electrets are analogous to magnets. 20 This surface charge of the 
container may be responsible for so-called specific ion adsorption, where certain ions are 
adsorbed out of solution by the container, providing an altered surface mi/eu.43 The surface 
charge is also responsible for the formation of the electric double-layer, which leads to 
adsorption and accumulation of counter-ions at the interfacial surface. These complex 
electrokinetic forces can enhance or inhibit platelet and coagulation effects, depending on 
specific ion effects. 8 The dielectric strengths (the electric potentials at the interface) of 
polymers are therefore commonly cited in describing their surface properties.12'18 It is known 
that a negative surface charge of a container partially resembles the negative charge of 
vascular endothelium, resulting in an inhibition of coagulation.37 
Hydrophilic and hydrophobic surfaces selectively adsorb different proteins, also affecting the 
platelet and coagulation responses. Initial fibrin monolayer formation mediates platelet 
adhesion, whereas albumin-coated surfaces reduce platelet adhesion.15 Nygren and 
colleagues found that, not only are proteins more highly bound to hydrophobic than 
hydrophilic glass surfaces, but platelets adhere and aggregate more readily on hydrophobic 
glass surfaces. These platelets displayed morphologic activation (pseudopodia, spreading 
aggregation) in addition to the adhesion mentioned on the hydrophobic surfaces, whereas, on 
the hydrophilic surfaces, only adhesion of single platelets were seen, not displaying any 
aggregation or activation. On the other hand, enzymatically active kallikrein was more highly 
adsorbed onto hydrophilic surfaces than hydrophobic ones.34 Proteins adhere to the surface 
of most polymers within 3 minutes. It has been shown that a good microdomain is one where 
hydrophilic and hydrophobic surfaces are tightly alternated (such as in block co-polymers), 
leading to differential protein adsorption, with albumin adhering to hydrophilic microdomains, 
and fibrinogen and y-globulin selectively adhering to hydrophobic microdomains. Inhibition of 
platelet adhesion and/or activation follows, depending on the polymer composition. If these 
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co-polymers are separated into their individual components, the same effect is not 
observed.35 
Contact angle, interfacial free energy, critical surface tensions (or "wettability"), and the 
optimum polar/apolar ratio hypotheses, as well as porosity and texture of the surface, are 
known to have complex and dynamic effects on coagulation.20 Various combinations are 
therefore responsible for the wide variation in coagulation response seen. 
Surface energy is a measure of the extent to which bonds are unsatisfied at the surface of a 
material. A surface energy is created by an asymmetric attraction of atoms into the bulk of 
the material, resulting in a net depletion of atoms on the surface, thereby leading to a surface 
tension. lnterfacial free energy is analogous to surface free energy, which determines if a 
liquid placed on a solid or other surface will disperse over the whole surface, or if it will remain 
as a droplet. This effect is dependent on the interfacial free energies of the two substances.20 
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At equilibrium, the contact angle equation describes the relationship between interfacial free 
energies of two substances and the angle formed by a droplet on a flat surface. For a liquid 
on a solid surface, the equation is: 
Ysfg = ys11 + Yllg cos 0 
where Ys/g is the interfacial free energy between the solid and gas 
Ys/1 is the interfacial free energy between the solid and the liquid, and 
Yl/g is the interfacial free energy between the liquid and gas 




SOLID Ys11 Ys!g 
It follows that different materials have different contact angles (e.g. Soda-lime-silica glass= 0° 
and Teflon®= 110°). The higher the contact angle, the more likely droplet-formation will 
occur on the surface. This can also be altered by surface texture or roughness, as well as dirt 
contamination and adsorption of polar gases onto the surfaces.20 
The critical surface tension (ye) of a solid surface describes its hydrophilicity or hydrophobicity. 
This Ye for a material is determined by measuring the different values of e formed by liquids 
with different y119 values. A high Ye reflects a relatively hydrophilic surface, and a hydrophobic 
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surface having a low Ye· It follows that a liquid with an interfacial free energy value higher 
than the Ye of a solid (y119 > Ye), will not spread on its surface, but when its interfacial free 
energy is lower than the solid's Ye (y119 < Ye), it will spread on the surface of the solid. 
20 
The surface tension of water is 72 mN/m, whereas the critical surface tension of 
polypropylene is only 22.1 mN/m, and that of polytetrafluoroethylene (Teflon®) is less still at 
18.5 mN/m. 11 The critical surface tension of polycarbonate is thought to be higher than that of 
polypropylene, as its surface is apparently more wettable. An exact value for the Ye of 
polycarbonate could not be found in extensive literature and Internet searches, however. 
The relevance of the critical surface tension of a solid is: 
a) Thrombosis in vivo increases as Ye increases, 
b) Faster clot formation occurs with increased Ye, 
c) Adhesion of tissue to artificial skin decreases as Ye increases, and 
d) The contact angle formed by cells in tissue culture decreases as Ye increases. 
The Ye is not perfect when explaining coagulation on the surface of all plastics, but provides a 
useful guide nonetheless.20 
The polar/apolar ratio hypothesis is based on the polar contribution of a surface to 
thrombogenicity. As the polar contribution to surface free energy increases, so the 
coagulability of the blood in contact increases too. The theory continues that a high 
dispersion force, low polarity surface favours the formation of a protein film, whereas 
materials with low dispersion forces and high polarity surface lead to weak adherence of 
proteins, leading to enhanced coagulability.8 
Coleman and colleagues disagree, however, with the interfacial free energy and the optimum 
polar/apolar ratio hypotheses being responsible for coagulation responses, due to the 
paradoxical effects seen with platelet adhesion and coagulation activation . They found the 
water content of plastics to cause these paradoxical effects on coagulation, where it was 
apparent that polymers with high water content inhibited platelet activation, but stimulated the 
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coagulation system, with the low water polymers seeming to produce inverse effects. 
Increased water content not only changes the surface characteristics of the polymer, but also 
the electric double-layer. 8 Both polypropylene and polycarbonate materials have low water 
contents (personal communication with Prof J Andrade, see references). Exact water 
contents were not available from manufacturers of the various tubes used in our studies. 
The coagulation response was not uniform for both the hetastarches we tested. After 
changing reservoir and/or dilution containers as described, interesting paradoxical responses 
were observed between the hetastarches tested (see figs 26-29), where one fluid appeared to 
have less coagulation effects than the other using one set of tubes, and the reverse with a 
separate methodology. Differences between these hetastarches are related to the molecular 
weight of the molecule and the carrier fluid of the starch. Sabax Hetastarch 6% ® has a 0.9% 
Saline suspension fluid, whereas Hextend® is suspended in a buffered, balanced electrolyte 
solution (similar to Ringer's Lactate). 
Worth considering is that the hetastarches, although both high molecular weight hydroxyethyl 
starches, are not identical. Sabax HES 6%® is a 450kDa, 0.7 substitution ratio starch, 
whereas Hextend® is a 670kDa, 0.75 substitution ratio starch. Hextend®, being a higher 
molecular weight starch, could possibly have a different sterical structure, as well as altered 
surface charge to HES. This could be very important in the interactions with coagulation. 
Electrolyte compositions differ between the fluids, especially calcium, magnesium and 
potassium. The interfacial effects of the container on calcium, an extremely important 
coagulation cofactor, could lead to its relative adsorption to the surface or a starch. When the 
presence of different plastic surfaces alter hetastarch charge or blood contact reactions 
further, amplification of previously small coagulation differences could occur due to the 
"stacking up" of activation or inhibitory coagulation effects. The role of pH is unknown in this 
study, however, it has been noted previously that pH does not play a significant role in 
coagulation effects of haemodilution in vitro. 42 
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Conclusion 
It is difficult to single out one specific factor responsible for coagulation changes seen in this 
trial , as there are so many interactions at the blood-polymer interface. For example, the 
wettable surface of a polycarbonate container is thought to activate coagulation, whereas the 
negative surface charge in some circumstances is thought to resemble the endothelium, this 
causing a degree of thromboresistance. On the other hand, some authors believe that a 
more polar surface increases coagulability. Ion adsorption out of the blood or solution also 
affects the electric bi-layer, which has knock-on effects on coagulability, especially if one 
considers the possible effects on an ion like calcium, essential for coagulation. The resultant 
coagulation response is due to a combination of all the factors mentioned, including the 
electrolyte composition of the fluids in contact. Even undiluted whole blood control samples 
we tested showed differences due to container effects. The different ionic compositions of the 
two tested hetastarch preparations, may also have a marked, sometimes paradoxical, effect 
on some of the mentioned electrokinetic and interfacial reactions described above. At this 
stage, one can only speculate what the exact causes could have been. 
It is likely that a marked effect occurs due to the interfacial charges, considering the electric 
bi-layer. Calcium would probably have a critical role here, and possibly this bi-layer could 
alter the dynamic relationship of calcium with blood and the starch involved. As mentioned in 
the discussion, this effect could be magnified when two slightly different starches are used in 
vitro. A strong suspicion would have to centre around the ionic and surface contact effects at 
the interface, altering dynamic starch, platelet, circulating procoagulant and anticoagulant 
balance, and calcium interactions. 
We observed the most paradoxical results when polycarbonate was combined with blood 
diluted in a balanced electrolyte hetastarch solution . This picture was not seen with 
haemodilution using either saline-based hetastarch, or with the balanced electrolyte 
hetastarch solution in polypropylene. It is evident that a dynamic effect occurs at the 
polycarbonate interface, especially when combined with Hextend® haemodilution. A 
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significant effect may well occur in the native, undiluted blood prior to haemodilution. These 
effects are exacerbated by Hextend® haemodilution. It is undoubted from our data that 
coagulation-changing effects occur, but exactly what they are at the interface is unknown at 
present. Coagulation proteins may adhere to the surface, thereby reducing their procoagulant 
effects when diluted or undiluted blood is placed in the TEG. Studies examining the 
molecular interactions at the interface will help us further explain these data. 
Polypropylene and polycarbonate tubes produce different responses on in vitro coagulation 
testing, especially when haemodilution is performed. Polycarbonate causes the most 
variation in results. It is thus inappropriate to use these tubes in studies of coagulation. 
Polypropylene and siliconised glass tubes are deemed to be more innocuous types of storage 
media.36'39 
These studies indicate that polycarbonate should not be used under any circumstances for 
storage of blood or in trials of haemodilution when coagulation testing is to be performed. 
Too many unknown coagulation effects occur at the polycarbonate-blood interface, especially 
when considering electrolyte and charge variability. These effects may result in skewed 
results, possibly incorrectly affecting clinical decision-making. 
Further research is certainly also needed to assess the variability in an in vivo setting, where 
accelerated tests (e.g. celite-activated TEG®) are routinely used in assessment of the clinical 
coagulation status of a patient. It is possible that polycarbonate containers used for initial 
storage of blood prior to TEG analysis could produce a hypocoagulable picture, purely due to 
the container effects. Incorrect clinical decision-making regarding the administration of blood 
products could result, unnecessarily exposing patients to transfusion-associated risks. 
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Appendix 1: 
Figure 26: r-times 
r-tlmes 












C·PP C·PC BSL·PP BSL·PC HES-PP HES-PC HEX-PP HEX-PC 
Where: 
C = Undiluted fresh whole blood 
PP = Polypropylene 
PC = Polycarbonate 
BSL = Balsol® 
HES = Sabax Hetastarch 6%® 
HEX = Hextend® 
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Figure 27: k-times 
k-tlmes 
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Appendix 2: 
Table 4: Raw Data Means (and Standard Deviations) 
MaxAmpl 
2 Stud 1 Stud 2 
C-PP 3.7(7.3) 42.3(6.5) 14.3(2.8) 18.5(2.9) 33.4(3.8) 23.3(3.4) 49.8(6.4) 47.9(3.5) 
C·PC 39.6(9.7) 45.2(5.3) 16.1(4.9) 26.1(4.6) 30.4(8.6) 17.6(3.6) 48.1(4.9) 41 .8(3.9) 
BSL-PP 35.0(10.4) 40.8(8.0) 10.6(3.2) 14.1(5.0) 39.5(12.2) 30.7(7.6) 45.2(4.3) 44.3(4.2) 
BSL-PC 33.1(9.4) 44.1(10.5) 9.9(3.2) 15.1(3.8) 42.9(11 .3) 29.3(7.0) 45.1(4.8) 42.9(3.7) 
HES-PP 50.8(12.4) 64.6(17.5) 17.8(5.1) 26.6(5.1) 27.9(6.1) 16.4(3.1) 37.4(6.0) 32.6(2.5) 
HES-PC 44.2(13.8) 50.4(13.6) 17.9(3.9) 22.0(5.4) 27.1(6.3) 20.8(5.5) 37.4(3.7) 35.4(5.2) 
HEX-PP 45.3(18.4) 53.2(10.1) 17.3(6.5) 23.7(4.7) 29.3(10.9) 19.0(3.1) 33.8(5.6) 31.4(2.4) 
HEX-PC 43.5(9.7) 58.1(13.3) 19.9(7.4) 30.8(9.7) 26.9(10.5) 16.4(4.6) 32.8(5.1) 27 .5(4.4) 
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Raw Data: Study 1 
Tube Fluid r k 
PP-d1 Control 21 10 
PP-d1 Control 28.5 12 
PP-d1 Control 34.5 14.5 
PP-d1 Control 40 18 
PP-d1 Control 37 14.5 
PP-d1 Control 32 12 
PP-d1 Control 31 .5 16 
PP-d1 Control 45 17.5 
PC-d1 Control 24 9.5 
PC-d1 Control 32.5 11 
PC-d1 Control 41 .5 18 
PC-d1 Control 35.5 15 
PC-d1 Control 47.5 20.5 
PC-d1 Control 35 12 
PC-d1 Control 47.5 20.5 
PC-d1 Control 53.5 22.5 
PC-d1 BSL 18 7.5 
PC-d1 BSL 30 7.5 
PC-d1 BSL 33 12.5 
PC-d1 BSL 47.5 14 
PC-d1 BSL 36.5 9.5 
PC-d1 BSL 28 6.5 
PC-d1 BSL 28 7.5 
PC-d1 BSL 43.5 14 
PP-d1 BSL 19 6.5 
PP-d1 BSL 27 9.5 
PP-d1 BSL 44 13 
PP-d1 BSL 42 11 
PP-d1 BSL 40.5 13.5 
PP-d1 BSL 25.5 7 
PP-d1 BSL 33.5 9 
PP-d1 BSL 48.5 15.5 
PC-d1 HES 21 .5 11 
PC-d1 HES 48.5 17 
PC-d1 HES 44 15.5 
PC-d1 HES 65.5 21 .5 
PC-d1 HES 53.5 22 
PC-d1 HES 31 16 
PC-d1 HES 38.5 17.5 
PC-d1 HES 51 22.5 
PP-d1 HES 31 .5 14.5 
PP-d1 HES 51 13 
PP-d1 HES 51 .5 18 
PP-d1 HES 50 17.5 
PP-d1 HES 69.5 24.5 
PP-d1 HES 36.5 10 
PP-d1 HES 54.5 22 
PP-d1 HES 62 22.5 
PC-d1 HEX 26.5 11 .5 
PC-d1 HEX 40.5 16 
PC-d1 HEX 40.5 16 
PC-d1 HEX 46.5 23 
PC-d1 HEX 48.5 33 
PC-d1 HEX 38 13 
PC-d1 HEX 47.5 27.5 
PC-d1 HEX 60 19.5 
PP-d1 HEX 24 11 
PP-d1 HEX 33.5 10 
PP-d1 HEX 36 15 
PP-d1 HEX 39.5 17.5 
PP-d1 HEX 52 21 
PP-d1 HEX 33 12 
PP-d1 HEX 74 28.5 
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All reservoir tubes = PP 
-d1 = dilution tubes 
PP-d1 = POLYPROPYLENE 
PC-d1 = POLYCARBONATE (SA) 
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Raw Data: Study 2 
Tube Fluid r k 
PP-d2 Control 51 19 
PP-d2 Control 38.5 16 
PP-d2 Control 35 15 
PP-d2 Control 34 18 
PP-d2 Control 48 23.5 
PP-d2 Control 45.5 16 
PP-d2 Control 39 19 
PP-d2 Control 47.5 21 .5 
PC-d2 Control 51 23.5 
PC-d2 Control 39 30 
PC-d2 Control 38.5 18 
PC-d2 Control 43.5 26 
PC-d2 Control 48 30.5 
PC-d2 Control 52 22 
PC-d2 Control 48 30 
PC-d2 Control 41 .5 29 
PC-d2 BSL 48 16 
PC-d2 BSL 35 14.5 
PC-d2 BSL 33 8.5 
PC-d2 BSL 32 13 
PC-d2 BSL 54 22 
PC-d2 BSL 52 14 
PC-d2 BSL 39.5 16 
PC-d2 BSL 59 17 
PP-d2 BSL 38.5 11 .5 
PP-d2 BSL 34.5 11 .5 
PP-d2 BSL 29.5 9 
PP-d2 BSL 39 11 .5 
PP-d2 BSL 49 16 
PP-d2 BSL 52 25 
PP-d2 BSL 36 12.5 
PP-d2 BSL 48 16 
PC-d2 HES 52.5 15.5 
PC-d2 HES 37.5 23 
PC-d2 HES 36 14.5 
PC-d2 HES 47.5 27 
PC-d2 HES 48 18.5 
PC-d2 HES 64 29.5 
PC-d2 HES 42 23 
PC-d2 HES 76 25 
PP-d2 HES 59.5 22.5 
PP-d2 HES 46 26.5 
PP-d2 HES 54 21 
PP-d2 HES 60.5 21 .5 
PP-d2 HES 91 35.5 
PP-d2 HES 93 27 
PP-d2 HES 54 27.5 
PP-d2 HES 59 31 .5 
PC-d2 HEX 57 30.5 
PC-d2 HEX 43 25.5 
PC-d2 HEX 47 23 
PC-d2 HEX 61 44 
PC-d2 HEX 70 46 
PC-d2 HEX 69 28.5 
PC-d2 HEX 41 .5 18 
PC-d2 HEX 76.5 31 
PP-d2 HEX 52 26 
PP-d2 HEX 44 22.5 
PP-d2 HEX 53 23 
PP-d2 HEX 58 33 
PP-d2 HEX 56.5 17 
PP-d2 HEX 47.5 24 
PP-d2 HEX 41 24 




































































































































































































All reservoir tubes = PP 
-d1 = dilution tubes 
PP-d2 = POLYPROPYLENE 
PC-d2=POL YCARBONA TE (UK) 
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